In this regard, a double-blind, randomized phase 3 study is underway evaluating the combination of an ICOS agonist, GSK3359609, with pembrolizumab versus placebo plus pembrolizumab in first-line treatment in patients with HNSCC R/M PD-L1 positive [39]. Here, CD274 is linked to head and neck squamous cell carcinoma.